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Open access under CAllergic contact dermatitis is a skin disease caused by an immunologic reaction to low molecular weight
compounds, so called haptens. These substances are commonly present in products used by humans in
daily life, such as in cosmetics and fragrances, as well as within chemical industry and in pharmaceuti-
cals. The frequent usage of these compounds in different applications has led to increasing incidences of
allergic contact dermatitis, which has become a substantial economic burden for society.
As a consequence, chemicals are routinely tested for their ability to induce skin sensitization, using ani-
mal models such as the murine Local Lymph Node Assay. However, recent legislations regulate the use of
animal models within chemical testing. Thus, there is an urgent need for in vitro alternatives to replace
these assays for safety assessment of chemicals.
Recently, we identiﬁed a signature of predictive genes, which are differentially regulated in the human
myeloid cell-line MUTZ-3 when stimulated with sensitizing compounds compared to non-sensitizing
compounds. Based on these ﬁndings, we have formulated a test strategy for assessment of sensitizing
compounds, called Genomic Allergen Rapid Detection, GARD. In this paper, we present a detailed method
description of how the assay should be performed.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Allergic contact dermatitis (ACD) is a type IV hypersensitivity
reaction, mediated by effector CD8+ and CD4+ T cells (Fonacier
et al., 2010). The disease is caused by low molecular weight
(LMW) compounds, which act as haptens that form a functional
allergen after binding to endogenous proteins present in skin. Dur-
ing the sensitization phase of ACD, the protein is taken up by der-
mal dendritic cells (DCs) that are present in the epidermis at the
site of exposure. Consequently, DCs will mature and migrate to lo-
cal lymph nodes, presenting fragments of the LMW complex on
either MHC class I or II, depending on the route of antigen uptake
(Friedmann, 2006). Provided that the DCs also become activated
and signal using co-stimulatory molecules, as reviewed in (Martin
et al., 2011), this antigen presentation will lead to differentiation of
naïve T cells into speciﬁc effector and memory T cells. Upon re-
exposure to the speciﬁc LMW compound, memory T cells elicit a
rapid immune response, mainly by the release of the proinﬂamma-
tory cytokines interferon (IFN) c and tumor necrosis factor (TNF) a.
LMW compounds able to induce ACD are termed skin sensitizers.+46 46 2224200.
e (H. Johansson), ann-soﬁe.
@immun.lth.se (C.A.K. Borre-
C BY-NC-ND license. Chemicals with sensitizing properties are commonly found
within chemical and pharmaceutical industry, and in products
used in everyday life such as cosmetics and fragrances, which
has led to increasing incidences of ACD, with prevalence rates of
up to 18.6% in speciﬁc cohorts in Europe (Mortz et al., 2001;
Nielsen et al., 2001), which corresponds approximately to 20% of
all reported cases of contact dermatitis, with the remaining 80%
being cases of immunologically non-speciﬁc irritant contact der-
matitis (Fonacier et al., 2010). In addition, contact dermatitis, both
irritant and allergic, accounts for 85–90% of all occupational skin
diseases among the working population of the Western world
(Friedmann, 2006), thereby causing a substantial economic burden
for society. In order to minimize the use of sensitizing compounds,
chemicals are routinely tested for their sensitizing potency. Such
assays are today performed with animal models, preferably the
murine local lymph node assay (LLNA) (Basketter et al., 2002).
However, the REACH (Registration, Evaluation, and Authorization
of Chemicals) regulation will have a huge impact on the number
of animals required for testing. In addition, the 7th Amendment
to the Cosmetics Directive (76/768/EEC) regulates the use of ani-
mals for testing cosmetic ingredients. Thus, there is an urgent need
of alternative in vitro assays for assessment of sensitizers, which
reﬂects clinical experience and that exhibits an improved reliabil-
ity and accuracy.
Consequently, several groups are currently developing animal-
free testing strategies, using a number of different approaches.
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tionship (QSAR) has e.g. shown promising results (Golla et al.,
2009; Gunturi et al., 2010). However, such in silico assays are likely
troubled by the diversity among molecular structures of sensitiz-
ers, since very similar structures give dissimilar sensitization re-
sults (Natsch, 2010). Furthermore, in chemico strategies predict
sensitization by measuring the peptide reactivity of compounds
(Gerberick et al., 2004). Still, the most extensively explored strat-
egy is in vitro cell based assays, among them the most frequent
ones being in vitro models of DCs, due to their key function as ini-
tiators of the immune response leading to skin sensitization.
Numerous cell systems and biomarkers have been suggested, such
as measurement of CD86 in the U-937 cell line (Python et al.,
2007), combined measurement of CD86 and CD54 in the THP-1 cell
line (Ashikaga et al., 2006; Sakaguchi et al., 2006), or monitoring of
the activity of transcription factors, such as nuclear factor-
erythroid 2-related factor 2 (NRF2) in a reporter cell line (Emter
et al., 2010). While these assays are functional and relevant, they
are all limited in their readout.
Recently, we presented a predictive biomarker signature in the
myeloid cell line MUTZ-3 (Johansson et al., 2011). We hypothe-
sized that, given a good in vitro DC model is available, such cells
could be explored for biomarkers for sensitization, due to their
roles as decision-makers in the immunologic response to foreign
substances. MUTZ-3 is a human acute myelomonocytic leukemia
cell line, which mimics primary DCs in terms of transcriptional
proﬁle and their ability to induce speciﬁc T cell responses (Larsson
et al., 2006; Masterson et al., 2002; Santegoets et al., 2006).
Furthermore, proliferating MUTZ-3 express an immunologically
relevant phenotype similar to immature primary DCs, with expres-
sion of CD1a, HLA-DR and CD54, as well as low expression of CD80
and CD86 (Johansson et al., 2011). Using a panel of reference chem-
icals, including 18 well-known sensitizers, 20 non-sensitizers and
vehicle controls, we were indeed able to identify differentially
regulated transcripts in MUTZ-3, depending on if the cells were
exposed to a sensitizer or a non-sensitizer. The identiﬁed tran-
scripts where found to be involved in immunologically relevant
pathways, regulating recognition of foreign substances and leading
to DC maturation. Thus, these biomarkers are potent predictors of
different sensitizers. We have developed the usage of this bio-
marker signature into a novel assay for skin sensitization, called
genomic allergen rapid detection, GARD. The assay is based on
the measurement of these transcripts, collectively termed the
GARD Prediction Signature, using a complete genome expression
array. Classiﬁcations of unknown compounds as sensitizers or
non-sensitizers are performed with a support vector machine
(SVM) model, trained on the 38 reference chemicals used for GARD
development. In this paper, we present a detailed method descrip-
tion for how to accurately predict skin sensitization, using GARD.2. Materials and methods
2.1. MUTZ-3 growth and seeding of cells for stimulation
The human myeloid leukemia-derived cell line MUTZ-3 (DSMZ,
Braunschweig, Germany) is maintained in a-MEM (Thermo Scien-
tiﬁc Hyclone, Logan, UT) supplemented with 20% (volume/volume)
fetal calf serum (Life Technologies, Carlsbad, CA) and 40 ng/ml
rhGM-CSF (Bayer HealthCare Pharmaceuticals, Seattle, WA), as de-
scribed (Johansson et al., 2011). A media change every 3–4 days is
recommended, or when cell-density exceeds 500.000–
600.000 cells/ml. Proliferating progenitor MUTZ-3 are used for
the assay, with no further differentiation steps applied. During
media exchange, cells should be counted and resuspended to
200.000 cells/ml. Working stocks of cultures should not be grownfor more than 20 passages or 2 months after thawing. For chemical
stimulation of cells, 1.8 ml MUTZ-3 is seeded in 24-well plates at a
concentration of 222.222 cells/ml. The compound to be used for
stimulation is added in a volume of 200 ll, diluting the cell density
to 200.000 cells/ml during incubation.
2.2. Phenotypic analysis of MUTZ-3
Prior to any chemical stimulation, a qualitative phenotypic anal-
ysis of MUTZ-3 is performed to ensure that proliferating cells are in
an immature stage. All cell surface staining and washing steps were
performed in PBS containing 1% BSA (w/v). Cells were incubated
with speciﬁc mouse monoclonal antibodies (mAbs) for 15 min at
4 C. The following mAbs were used for ﬂow cytometry: FITC-con-
jugated CD1a (DakoCytomation, Glostrup, Denmark), CD34, CD86,
and HLA-DR (BD Biosciences, San Diego, CA), PE-conjugated CD14
(DakoCytomation), CD54 and CD80 (BD Biosciences). Mouse IgG1,
conjugated to FITC or PE were used as isotype controls (BD
Biosciences) and propidium iodide (PI) (BD Biosciences) was used
to assess cell viability. FACSDiva software was used for data acqui-
sition with FACSCanto II instrument (BD Bioscience). 10,000 events
were acquired, gates were set based on light scatter properties to
exclude debris and non-viable cells, and quadrants were set accord-
ing to the signals from isotype controls. Further data analysis was
performed, using FCS Express V3 (De Novo Software, Los Angeles,
CA).
2.3. Chemical handling and assessment of cytotoxicity
All chemicals should be stored according to instructions from
the supplier, in order to ensure stability of compounds. Chemicals
should be dissolved in water when possible or DMSO for hydro-
phobic compounds. As many chemicals will have a toxic effect
on the MUTZ-3 cells, this toxicity needs to be monitored. Some
chemicals are poorly dissolved in cell media; therefore the maxi-
mum soluble concentration needs to be assessed as well. The
chemical that is to be tested should be titrated to concentrations
ranging from 1 lM to the maximum soluble concentration in cell
media. For freely soluble compounds, 500 lM should be the upper
end of the titration range. For cell stimulations, chemicals should
be dissolved in its appropriate solvent as 1000 stocks of target
in-well concentration, called stock A. A 10 stock, called stock B,
is prepared by taking 10 ll of stock A to 990 ll of cell media.
200 ll of stock B is then added to the wells containing 1.8 ml
seeded cells. For the samples dissolved in DMSO, the in-well con-
centration of DMSO will thus be 0.1%. Following incubation for
24 h at 37 C and 5% CO2, harvested cells are stained with PI and
analyzed with a ﬂow cytometer. The relative viability of cells stim-
ulated with each concentration in the titration range are calculated
as
Relative vialbility ¼ fraction of viable stimulated cells
fraction of viable unstimulated cells
 100
For toxic compounds, the concentration yielding 90% relative
viability (Rv90) should be used for the GARD assay. For non-toxic
compounds, a concentration of 500 lM should be used if possible.
For non-toxic compounds that are insoluble at 500 lM in cell med-
ia, the highest soluble concentration should be used. Whichever of
these three criteria is met, only one concentration will be used for
the genomic assay. The concentration to be used for any given
chemical is termed the ‘GARD input concentration’.
2.4. Chemical exposure of cells for GARD
Once the testing concentration for chemicals to be assayed is
established, the cells are stimulated again as described above, this
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known compounds should be assayed in biological duplicates, per-
formed at different time-points and different cell cultures. At each
experiment, duplicate wells are used for each stimulation, provid-
ing two technical replicates for each biological replicate. Following
24 h incubation for 24 h at 37 C and 5% CO2, cells from one well
are lysed in 1 ml TRIzol reagent (Life Technologies) and stored at
20 C until RNA extraction. 200.000 cells/well is a large surplus
of what is required for cDNA preparation (see below), but a second
sample (technical replicate) is stored as backup. In parallel, a small
sample of stimulated cells are taken for PI staining and analysis
with ﬂow cytometry, to ensure the intended viability of the cells
is reached.2.5. Preparation of cDNA and gene chip hybridization
RNA isolation from lysed cells is performed as described by the
TRIzol supplier (Life Technologies). A minimum of 300 ng total RNA
is required to perform preparation of cDNA. The preparation of la-
beled sense DNA is performed according to Affymetrix GeneChip™
whole transcript (WT) sense target labeling assay (100 ng Total
RNA labeling protocol), using the recommended kits and controls
(Affymetrix, Santa Clara, CA). Hybridization, washing and scanning
of the Human Gene 1.0 ST arrays should be performed according to
the manufacturer’s protocol (Affymetrix).2.6. Data acquisition and analysis
The microarray data should be normalized and quality checked
with the RMA algorithm, using Affymetrix expression console
(Affymetrix). At this point, data should be merged with existing
training data created during GARD development (Johansson et al.,
2011). The readout for the assay is the decision value output from
a support vector machine (SVM) (Noble, 2006). SVMs are con-
structed in R (R Development Core Team, 2008), with the addi-
tional package e1071 (R package e1071). The SVM should be
trained on the training data available, using only the 200 analytes
in the GARD Prediction Signature (Johansson et al., 2011). The sam-
ples that are being assayed are then evaluated by the trained and
frozen SVM, as a test set. The classiﬁcation of a sample as a sensi-
tizer or a non-sensitizer is based on the SVM prediction; a positive
decision value means a sample is a sensitizer, and a negative deci-
sion value means a sample is a non-sensitizer. The SVM prediction
is in this paper illustrated with a Sammon projection (Sammon,
1969) constructed in R, and with a principal component analysis
(PCA) (Ringner, 2008) constructed in Qlucore Omics Explorer 2.1
(Qlucore AB, Lund, Sweden).3. Results
3.1. GARD background and workﬂow
The complete workﬂow of the GARD assay is summarized in
Fig. 1A. First, a qualitative phenotypic analysis of MUTZ-3 is per-
formed to ensure that proliferating cells are in an immature stage.
As MUTZ-3 is known to be a heterogeneous population of cells,
variations in surface antigen expression does commonly occur.
However, an example of a MUTZ-3 phenotype in unstimulated
cells has been previously reported (Johansson et al., 2011). Further-
more, the viability of MUTZ-3 prior to stimulation should be as-
sessed with PI staining. The viability criteria for accepting a cell
culture for use in the assay is set to >85%. Instructions on how to
gate cells for phenotypic quality control and viability analysis are
provided in Fig. 1B and C, respectively.The GARD input concentration of chemicals to be assayed is
determined as described in the material & methods section. Fol-
lowing 24 h incubation, cells are harvested, RNA is isolated, cDNA
is prepared and arrays are hybridized, washed and scanned as de-
scribed. Once the array data is acquired, it should be merged with a
training data set, which consists of measurements of all 38 refer-
ence chemicals run during assay development (Johansson et al.,
2011). The data is normalized with Affymetrix’s RMA algorithm.
A data set consisting of both train data and any new samples that
are to be assayed is now available for analysis.
At this point, an SVM is trained on the training data. The trained
SVM is a model, or an equation, that describes the hyperplane that
best separates sensitizers from non-sensitizers in the train data.
This model can then be applied to predict any unknown samples,
i.e. the test data, as either sensitizers or non-sensitizers. The
trained data is shown in a 3D PCA plot based on the GARD Predic-
tion Signature in Fig. 1D, with a hyperplane represented as a 2D
plane. This illustrates the classiﬁcations performed by the SVM,
visible and interpretable by the human eye, as unknown samples
of a hypothetical test set (dark red) that group together with sen-
sitizers of the training data (bright red) on one side of the hyper-
plane would be classiﬁed as sensitizers, while unknown samples
that group together with non-sensitizers of the training data
(green) on the other side of the hyperplane would be classiﬁed
as non-sensitizers. The actual SVM output is displayed as predic-
tion values, corresponding to the Euclidean distance between the
sample to be classiﬁed and the hyperplane. Thus, the decision va-
lue for any given sample represents the position of the sample in
comparison to the hyperplane. Consequently, a positive prediction
value denotes a sensitizer, and a negative value denotes a non-sen-
sitizer. In addition, potency of a predicted sensitizer will be deter-
mined by the absolute value of the decision value, i.e. the actual
distance to the hyperplane. A large decision value corresponds to
a strong sensitizer, while a small decision value corresponds to a
weaker sensitizer.
3.2. An example of how to assess the sensitizing capacity of unknown
chemicals
In this section, the assessment of two chemicals will be exem-
pliﬁed, step by step. We will study the two compounds 2-nitro-
1,4-phenylendiamine, a strong sensitizer according to the LLNA,
and methyl salicylate, a non-sensitizer. Both of these compounds
were used for the development of GARD, but for the sake of this
exercise, they will be removed from the available data set and trea-
ted as unknown samples. Triplicate samples are available of each
stimulation, providing true biological replicates.
The two compounds are freely soluble in cell media to a concen-
tration of 500 lM, if they are ﬁrst dissolved in DMSO. Thus, when
determining the GARD input concentration, 500 lM will be the
high end of the titration range. Cell stimulations were performed
as described, and harvested cells were stained with PI (Fig. 2A).
The relative viability of cells stimulated with 2-nitro-1,4-phenyl-
endiamine decreases with increasing stimuli concentration. The
Rv90 value for this compound is identiﬁed at a concentration of
300 lM. In contrast, methyl salicylate does not have any cytotoxic
effect on MUTZ-3, as the relative viability remains unchanged with
increasing stimuli concentration. Thus, the GARD input concentra-
tions for 2-nitro-1,4-phenylendiamine and methyl salicylate are
300 and 500 lM, respectively.
Once the GARD input concentration for all samples to be as-
sayed are established, cell stimulations for 24 h are repeated. Cells
are harvested, RNA is isolated, cDNA is prepared and arrays are
hybridized as described. Both stimulations are performed in tripli-
cate, independent experiments. Thereafter, the array data from the
triplicate stimulations are normalized, together with available
Fig. 1. GARD Workﬂow. (A) A schematic view of the different steps of sensitizer assessment using GARD. (1) MUTZ-3 cells are phenotyped, ensuring that unstimulated cells
are in an immature stage. (2) The chemicals to be tested are titrated and investigated for cytotoxic effects. A GARD input concentration is established. (3) MUTZ-3 cells are
stimulated with the chemicals, using the GARD input concentration. (4) A cell sample is stained with PI, ensuring that the desired relative viability is reached. (5) RNA is
extracted, cDNA is synthesized and arrays are hybridized, according to standard protocols. (6) Following scanning of arrays, expression data is acquired. (7) The data is
merged with available trained data. (8) The trained data and test data are normalized with an RMA normalization algorithm. (9) An SVM is trained and the SVMmodel is then
used for predicting the test data. An output will be given for each sample in the form of a decision value. (B) Gating instructions for phenotypic analysis of MUTZ-3 cells,
showing unstimulated cells stained with isotype controls. A gate is set in the FSC/SSC-plot to exclude dying cells and cell debris. Observing only gated cells, quadrants are set
according to signals of isotype controls. (C) Gating instructions for viability analysis using propidium iodide. No gates are set in the FSC/SSC-plot. Dead cells are distinguished
from live cells by their uptake of Propidium Iodide and ﬂuorescence in the PE-channel. (D) SVM predictions, illustrated with a 3D PCA based on the 200 genes of GARD
prediction signature. Unknown samples are plotted in the PCA without contributing to the principal components. The SVM hyperplane is in three dimensions illustrated with
a 2D plane, from which decision values are calculated, serving as the basis for classiﬁcation.
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data refer to the remaining 36 stimulations and vehicle controls
used for the establishment of the GARD Prediction Signature
(Johansson et al., 2011), a total of 131 arrays. At this point, the
training data is used for training an SVM model. The model is then
used to classify the test data, i.e. 2-nitro-1,4-phenylindiamine and
methyl salicylate, as either sensitizer or non-sensitizer (Fig. 2B).
The obtained decision values for this experiment are presented in
Table 1.
3.3. Robustness, stability and reproducibility
The reproducibility of GARD was determined by assessing the
correlation between the triplicate samples of each of the 38 refer-
ence chemicals used for assay development. RNA from these trip-
licate samples were collected at different days and on different
batches of cells. Thus, biological variations in terms of cell cycle
and growth rate are integrated in the assessment of reproducibil-
ity, as well as technical variation during RNA isolation, array
hybridization and variation between array batches.
The variation in raw signal was assessed by studying Pearson’s
correlation coefﬁcient (Table 2). The correlation coefﬁcient is cal-culated by comparing data for the 200 genes in the GARD Predic-
tion Signature, or for data derived from the complete array. For
the GARD Prediction Signature, the correlation coefﬁcient is 0.99
or above in 86% of all comparisons made. The lowest correlation
between replicates is observed for penicillin G and p-phenylendi-
amine, with a coefﬁcient of 0.97. When comparing replicates based
on the full array, only Penicillin G has a coefﬁcient below 0.99.
Thus, the data is highly reproducible, with stable expression levels
of the measured transcripts in technical and biological replicates.
The variation in decision, naturally dependent on the raw signal
values will have an impact on how samples are classiﬁed. As can be
seen in Fig. 2B, the replicates of both 2-nitro-1,4-phenylendiamine
group closely together in a 2D Sammon projection, indicating a
strong robustness and reproducibility of the assay. If triplicate
samples of any one stimulation end up on both sides of the hyper-
plane, it should be regarded as a sensitizer. Indeed, while the cutoff
of a sample being a sensitizer or a non-sensitizer is currently set to
zero, this cutoff should and will be evaluated in connection with
pre-validation of the assay. Furthermore, a sample being ambigu-
ously classiﬁed by the SVM is likely a weak sensitizer, as the abso-
lute value of the decision value may be correlated to the potency of
the sensitizer; the further away from the cloud of negative samples
Fig. 2. Sensitizer assessment using GARD. Methyl salicylate and 2-nitro-1,4-
phenilendiamine are used to exemplify how unknown samples are classiﬁed as
either sensitizer or non-sensitizer. (A) The GARD input concentrations are deter-
mined by studying cytotoxic effects induced by the chemicals. Shown data are
averages of duplicate samples. Data was obtained through propidium iodide
staining and analysis with ﬂow cytometry. No gates were set, and the reported
viability is relative to unstimulated control. (B) Sammon projection in two
dimensions of samples in the train set together with the two compounds to be
classiﬁed. The hyperplane from which SVM decision values are measured is in this
2D representation illustrated with a line, exemplifying how classiﬁcations are
made.
Table 1
SVM predictions of test data.
Sample SVM prediction value SVM classiﬁcation
2-Nitro-1,4-phenilindiamine 1 6.3 Sensitizer
2-Nitro-1,4-phenilindiamine 2 5.1 Sensitizer
2-Nitro-1,4-phenilindiamine 3 5.4 Sensitizer
Methyl salicylate 1 1.8 Non-sensitizer
Methyl salicylate 2 1.8 Non-sensitizer
Methyl salicylate 3 0.9 Non-sensitizer
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discussed in (Johansson et al., 2011).4. Discussion
Prediction of a compound’s ability to induce skin sensitization is
an important aspect of safety assessment of chemicals, and is cur-
rently performed with animal models, such as the murine LLNA.
However, a number of factors, such as the REACH legislation and
the 7th amendment to the Cosmetics Directive, make animal mod-
els unsuitable for assessment of sensitization. Furthermore, these
assays are known to not correlate perfectly with clinical experience
of human data. Indeed, the Interagency Coordinating Committee
on the Validation of Alternative Methods (ICCVAM) reported the
accuracy of the LLNA to be 72% (Haneke et al., 2001).
Genomic allergen rapid detection, GARD, is a novel assay for
assessment of sensitization. It is based on a genomic readout, mea-
suring 200 transcripts in the myeloid cell line MUTZ-3 following
compound stimulation. The 200 transcripts, collectively called
GARD Prediction Signature, participate in signaling pathways that
are involved with recognition of foreign substances. A number of
these pathways, such as nuclear factor-erythroid-related factor 2
(NRF2) mediated oxidative response, aryl hydrocarbon receptor
(AHR) signaling and Toll-like receptor (TLR) signaling, are known
to lead to transcription of cytoprotective enzymes and DC matura-
tion (Johansson et al., 2011) as a response to xenobiotic challenges.
Thus, GARD utilizes human MUTZ-3 as an in vitro DC model, taking
advantage of its decision-making role in the immune response
leading to skin sensitization for predicting sensitizing potency in
unknown chemicals.
As a consequence of being an assay with a biomarker signature
as readout, simultaneously monitoring a number of different cell
events, GARD is well suited to detect positive compounds from a
wide chemical space. The assay has been shown to be robust and
highly reproducible, as well as accurate, with respect to the 38 ref-
erence compounds run so far. Although GARD has yet to go
through a formal pre-validation, a thorough cross-validation has
been performed during assay development, estimating the accu-
racy of the assay to >95% (Johansson et al., 2011). An internal study
that will test the accuracy of GARD is currently being performed,
using an additional panel of reference chemicals, including eight
sensitizers and four non-sensitizers. In addition, 27 blinded sam-
ples have been made available to us from third parties, which will
be assayed together with our internal validation panel. The results
from these experiments are currently under analysis.
The great versatility that comes with analyzing the complete
genome of cells allows for further development and broadening
of the assay. Studies are currently being performed to evaluate
GARD’s applicability for respiratory sensitizers, both chemical hap-
tens and proteins. Methods for assessment of respiratory sensitiza-
tion are greatly underdeveloped, with no validated assay available
to date (Verstraelen et al., 2008). However, efforts are being made
to develop cell-based assays for sensitization of the respiratory
tract, using both DC-like cell lines such as THP-1 (Verstraelen
et al., 2009c), as well as epithelial cell lines such as BEAS-2B (Verst-
raelen et al., 2009b) and A549 (Verstraelen et al., 2009a). Further-
more, chemical reactivity assays are being explored within
respiratory sensitization as well (Lalko et al., 2011). However, pep-
tide reactivity has been shown to be a common feature for many
sensitizers of both skin and respiratory tract, which would make
it hard for such assays to discriminate between the two. In con-
trast, we envision GARD as being a single assay for both groups
of sensitizers and this would be accomplished by having separate
or overlapping Prediction Signatures for skin and respiratory sensi-
tizers. The prerequisite for accomplishing such an assay is that
stimulated MUTZ-3 possesses the informational content necessary
for separating respiratory sensitizers from negative controls, i.e.
that such a respiratory Prediction Signature can be identiﬁed.
Indeed, we have recently identiﬁed a biomarker signature that
Table 2
Correlation between the three replicates of all reference compounds used for assay development. All values are calculated Pearson coefﬁcients between two replicates.
Stimulation GARD prediction signature Full array
1 vs 2 1 vs 3 2 vs 3 1 vs 2 1 vs 3 2 vs 3
Non-sensitizers
1-Butanol 0.99 0.99 1.00 0.99 0.99 1.00
4-Aminobenzoic acid 0.99 0.98 0.98 0.99 0.99 0.99
Benzaldehyde 1.00 1.00 1.00 1.00 1.00 1.00
Chlorobenzene 0.99 0.99 1.00 1.00 1.00 1.00
Diethyl phthalate 1.00 0.99 0.99 1.00 0.99 1.00
Dimethyl formamide 0.99 0.99 1.00 0.99 0.99 1.00
Ethyl vanillin 1.00 1.00 0.99 0.99 0.99 0.99
Glycerol 0.99 1.00 1.00 0.99 0.99 1.00
Isopropanol 0.99 0.99 0.99 0.99 0.99 0.99
Lactic acid 0.99 0.99 0.99 0.99 0.99 0.99
Methyl salicylate 0.99 0.99 0.99 0.99 0.99 0.99
Octanoic acid 1.00 0.99 0.99 1.00 1.00 1.00
Phenol 1.00 0.99 1.00 1.00 1.00 1.00
p-Hydroxybenzoic acid 0.99 0.99 0.99 0.99 0.99 0.99
Potassium permanganatea 1.00 – – 1.00 – –
Propylene glycol 1.00 1.00 1.00 1.00 1.00 1.00
Salicylic acid 1.00 0.99 0.99 1.00 0.99 1.00
Sodium dodecyl sulfate 0.99 0.99 0.99 1.00 0.99 0.99
Tween 80 0.99 0.99 0.99 1.00 0.99 0.99
Zinc sulfate 0.99 0.99 0.98 1.00 0.99 0.99
Sensitizers
2,4-Dinitrocholorobenzene 0.99 0.99 0.99 0.99 0.99 0.99
2-Aminophenol 0.99 0.99 0.99 1.00 1.00 0.99
2-Hydroxyethyl acrylate 0.99 0.99 0.98 0.99 0.99 0.99
2-Mercabtobenzothiazole 1.00 0.99 0.99 1.00 0.99 0.99
2-Nitro-1,4-phenylendiamine 0.99 0.99 0.99 1.00 0.99 1.00
Cinnamic alcohol 0.99 0.99 0.98 0.99 0.99 0.99
Ethylendiamine 0.98 0.99 0.99 0.99 0.99 0.99
Eugenol 0.99 1.00 0.99 1.00 1.00 1.00
Formaldehyde 1.00 0.99 0.99 0.99 0.99 0.99
Geraniol 0.99 1.00 0.99 0.99 0.99 0.99
Glyoxal 0.99 1.00 0.99 0.99 1.00 1.00
Hexylcinnamic aldehyde 0.98 0.99 0.99 0.99 0.99 0.99
Isoeugenol 0.99 0.99 0.99 0.99 0.99 0.99
Kathon CG (MC/MCI) 0.99 0.99 0.99 1.00 1.00 1.00
Penicillin G 0.99 0.97 0.97 0.99 0.99 0.98
Potassium dichromate 1.00 0.99 0.99 0.99 0.99 0.99
p-Phenylendiamine 0.98 0.99 0.97 0.99 0.99 0.99
Resorcinol 1.00 1.00 1.00 1.00 1.00 1.00
a Only two replicates of potassium permanganate were used during assay development, due to a faulty array.
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controls, with results currently being summarized in a manuscript.
While the analysis of the complete genome has been powerful
during assay development and identiﬁcation of the GARD predic-
tion signature, the assay in its ﬁnal form might beneﬁt from a tech-
nological platform transfer to multiplex quantitative PCR or
custom arrays. Such a platform transfer, along with the necessary
reduction of prediction signature sizes, will be evaluated in con-
nection to pre-validation.
The transferability of the assay remains to be tested although
we foresee no immediate problems with the technology transfer.
Maintenance of the MUTZ-3 cell line, chemical exposure and ﬂow
cytometric analysis are all steps easily transferred between labora-
tories, as demonstrated recently for the DC migration assay (Rees
et al., 2011). The scripts used to perform SVM classiﬁcations are
written for R, an open source program freely available for down-
load (R Development Core Team, 2008).
In conclusion, GARD is a novel assay for assessment of sensitiza-
tion. The powerful analysis of the full genome of MUTZ-3, or parts
thereof, using so called Prediction Signatures, allows for a robust
readout that may answer questions of unknown chemicals’ ability
to induce skin or respiratory sensitization, or both. The assay is
simple to perform, with a majority of the laboratory steps being
conducted according to standardized protocols provided by plat-form suppliers, thus constituting an attractive replacement for ani-
mal tests.
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